Frosina G, Rossi O, Arena G, Gentile S L, Bruzzone E, Abbondandolo A
Laboratory of Mutagenesis, IST, V. le Benedetto XV, Genova, Italy.
Cancer Lett. 1990 Dec 3;55(2):153-8. doi: 10.1016/0304-3835(90)90026-t.
The O6-alkylguanine-DNA alkyltransferase (AT) activity in different kinds of human brain tumors was investigated. Twenty-seven brain tumors were analysed. Twenty-five of them showed proficient AT activity with values ranging between 20 and 722 fmol AT/mg protein. The two AT-deficient tumors observed were an oligodendroglioma and an astrocytoma. The relationship between the different histological kinds of tumor, with respect to the AT activity was: meningeomas greater than sarcomas greater than glioblastomas greater than astrocytomas greater than oligodendrogliomas greater than neurinomas greater than lymphomas. The proposal of Kohn (DNA filter elution methods in anticancer drug development. In: Concepts, Clinical Developments, and Therapeutic Advances in Cancer Chemotherapy. Editor: F.M. Muggia. Martinus Nijhoff Publishers, Boston) to confine treatments with alkylating antineoplastic agents to AT-deficient tumors, is discussed.
对不同类型人脑肿瘤中的O6-烷基鸟嘌呤-DNA烷基转移酶（AT）活性进行了研究。分析了27例脑肿瘤。其中25例显示出高效的AT活性，其值在20至722 fmol AT/毫克蛋白质之间。观察到的两例AT缺陷型肿瘤分别为少突胶质细胞瘤和星形细胞瘤。不同组织学类型肿瘤之间关于AT活性的关系为：脑膜瘤＞肉瘤＞胶质母细胞瘤＞星形细胞瘤＞少突胶质细胞瘤＞神经鞘瘤＞淋巴瘤。讨论了Kohn的提议（抗癌药物开发中的DNA滤膜洗脱方法。载于：《癌症化疗的概念､临床进展和治疗进展》。编辑：F.M. Muggia。Martinus Nijhoff出版社，波士顿），即将烷化抗肿瘤药的治疗局限于AT缺陷型肿瘤。
